Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma

Camillo Porta, Susanne Osanto, Alain Ravaud, Miguel Angel Climent, Ulka Vaishampayan, Dorothy A. White, Patricia Creel, Brenda Dickow, Patricia Fischer, Suzanne Sweeney Gornell, Federica Meloni, Robert J. Motzer

Research output: Contribution to journalArticle

Abstract

Purpose: In April 2009, an expert group of 11 physicians and clinical nurses met to discuss the management of selected adverse events associated with the use of everolimus for the treatment of metastatic renal cell carcinoma (mRCC). Everolimus is an orally administered inhibitor of the mammalian target of rapamycin that recently received approval from the European Medicines Agency for the treatment of advanced RCC that has progressed on or after treatment with vascular endothelial growth factor (VEGF)-targeted therapy, and from the United States Food and Drug Administration for treatment of advanced RCC after failure of sorafenib or sunitinib. Before the approval of everolimus, no standard therapy existed for the treatment of mRCC after failure of VEGF-targeted therapy. RECORD-1 (Renal Cell cancer treatment with Oral RAD001 given Daily) was the pivotal multicenter, phase III, randomised, double-blind, placebo-controlled trial of everolimus that led to approval for patients with disease progression on or after treatment with VEGF-targeted agents. Safety data from RECORD-1 were reviewed by these clinicians, all of whom had experience using everolimus in patients with mRCC. Adverse events discussed were non-infectious pneumonitis, infections, stomatitis and metabolic abnormalities. Results: The outcome of this discussion is summarised here. Guidance for management of these adverse events is provided. Both clinicians and patients should be aware of the potential side-effects of everolimus and understand that these side-effects are manageable with standard care to optimise patient benefit.

Original languageEnglish
Pages (from-to)1287-1298
Number of pages12
JournalEuropean Journal of Cancer
Volume47
Issue number9
DOIs
Publication statusPublished - Jun 2011

Fingerprint

Renal Cell Carcinoma
Vascular Endothelial Growth Factor A
Therapeutics
Everolimus
Stomatitis
Sirolimus
United States Food and Drug Administration
Disease Progression
Pneumonia
Nurses
Placebos
Physicians
Safety
Infection

Keywords

  • Adverse events
  • Everolimus
  • Patient management
  • Renal cell carcinoma
  • Safety

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. / Porta, Camillo; Osanto, Susanne; Ravaud, Alain; Climent, Miguel Angel; Vaishampayan, Ulka; White, Dorothy A.; Creel, Patricia; Dickow, Brenda; Fischer, Patricia; Gornell, Suzanne Sweeney; Meloni, Federica; Motzer, Robert J.

In: European Journal of Cancer, Vol. 47, No. 9, 06.2011, p. 1287-1298.

Research output: Contribution to journalArticle

Porta, C, Osanto, S, Ravaud, A, Climent, MA, Vaishampayan, U, White, DA, Creel, P, Dickow, B, Fischer, P, Gornell, SS, Meloni, F & Motzer, RJ 2011, 'Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma', European Journal of Cancer, vol. 47, no. 9, pp. 1287-1298. https://doi.org/10.1016/j.ejca.2011.02.014
Porta, Camillo ; Osanto, Susanne ; Ravaud, Alain ; Climent, Miguel Angel ; Vaishampayan, Ulka ; White, Dorothy A. ; Creel, Patricia ; Dickow, Brenda ; Fischer, Patricia ; Gornell, Suzanne Sweeney ; Meloni, Federica ; Motzer, Robert J. / Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. In: European Journal of Cancer. 2011 ; Vol. 47, No. 9. pp. 1287-1298.
@article{1d23aa04f35c43a9948d24808f878f11,
title = "Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma",
abstract = "Purpose: In April 2009, an expert group of 11 physicians and clinical nurses met to discuss the management of selected adverse events associated with the use of everolimus for the treatment of metastatic renal cell carcinoma (mRCC). Everolimus is an orally administered inhibitor of the mammalian target of rapamycin that recently received approval from the European Medicines Agency for the treatment of advanced RCC that has progressed on or after treatment with vascular endothelial growth factor (VEGF)-targeted therapy, and from the United States Food and Drug Administration for treatment of advanced RCC after failure of sorafenib or sunitinib. Before the approval of everolimus, no standard therapy existed for the treatment of mRCC after failure of VEGF-targeted therapy. RECORD-1 (Renal Cell cancer treatment with Oral RAD001 given Daily) was the pivotal multicenter, phase III, randomised, double-blind, placebo-controlled trial of everolimus that led to approval for patients with disease progression on or after treatment with VEGF-targeted agents. Safety data from RECORD-1 were reviewed by these clinicians, all of whom had experience using everolimus in patients with mRCC. Adverse events discussed were non-infectious pneumonitis, infections, stomatitis and metabolic abnormalities. Results: The outcome of this discussion is summarised here. Guidance for management of these adverse events is provided. Both clinicians and patients should be aware of the potential side-effects of everolimus and understand that these side-effects are manageable with standard care to optimise patient benefit.",
keywords = "Adverse events, Everolimus, Patient management, Renal cell carcinoma, Safety",
author = "Camillo Porta and Susanne Osanto and Alain Ravaud and Climent, {Miguel Angel} and Ulka Vaishampayan and White, {Dorothy A.} and Patricia Creel and Brenda Dickow and Patricia Fischer and Gornell, {Suzanne Sweeney} and Federica Meloni and Motzer, {Robert J.}",
year = "2011",
month = "6",
doi = "10.1016/j.ejca.2011.02.014",
language = "English",
volume = "47",
pages = "1287--1298",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "9",

}

TY - JOUR

T1 - Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma

AU - Porta, Camillo

AU - Osanto, Susanne

AU - Ravaud, Alain

AU - Climent, Miguel Angel

AU - Vaishampayan, Ulka

AU - White, Dorothy A.

AU - Creel, Patricia

AU - Dickow, Brenda

AU - Fischer, Patricia

AU - Gornell, Suzanne Sweeney

AU - Meloni, Federica

AU - Motzer, Robert J.

PY - 2011/6

Y1 - 2011/6

N2 - Purpose: In April 2009, an expert group of 11 physicians and clinical nurses met to discuss the management of selected adverse events associated with the use of everolimus for the treatment of metastatic renal cell carcinoma (mRCC). Everolimus is an orally administered inhibitor of the mammalian target of rapamycin that recently received approval from the European Medicines Agency for the treatment of advanced RCC that has progressed on or after treatment with vascular endothelial growth factor (VEGF)-targeted therapy, and from the United States Food and Drug Administration for treatment of advanced RCC after failure of sorafenib or sunitinib. Before the approval of everolimus, no standard therapy existed for the treatment of mRCC after failure of VEGF-targeted therapy. RECORD-1 (Renal Cell cancer treatment with Oral RAD001 given Daily) was the pivotal multicenter, phase III, randomised, double-blind, placebo-controlled trial of everolimus that led to approval for patients with disease progression on or after treatment with VEGF-targeted agents. Safety data from RECORD-1 were reviewed by these clinicians, all of whom had experience using everolimus in patients with mRCC. Adverse events discussed were non-infectious pneumonitis, infections, stomatitis and metabolic abnormalities. Results: The outcome of this discussion is summarised here. Guidance for management of these adverse events is provided. Both clinicians and patients should be aware of the potential side-effects of everolimus and understand that these side-effects are manageable with standard care to optimise patient benefit.

AB - Purpose: In April 2009, an expert group of 11 physicians and clinical nurses met to discuss the management of selected adverse events associated with the use of everolimus for the treatment of metastatic renal cell carcinoma (mRCC). Everolimus is an orally administered inhibitor of the mammalian target of rapamycin that recently received approval from the European Medicines Agency for the treatment of advanced RCC that has progressed on or after treatment with vascular endothelial growth factor (VEGF)-targeted therapy, and from the United States Food and Drug Administration for treatment of advanced RCC after failure of sorafenib or sunitinib. Before the approval of everolimus, no standard therapy existed for the treatment of mRCC after failure of VEGF-targeted therapy. RECORD-1 (Renal Cell cancer treatment with Oral RAD001 given Daily) was the pivotal multicenter, phase III, randomised, double-blind, placebo-controlled trial of everolimus that led to approval for patients with disease progression on or after treatment with VEGF-targeted agents. Safety data from RECORD-1 were reviewed by these clinicians, all of whom had experience using everolimus in patients with mRCC. Adverse events discussed were non-infectious pneumonitis, infections, stomatitis and metabolic abnormalities. Results: The outcome of this discussion is summarised here. Guidance for management of these adverse events is provided. Both clinicians and patients should be aware of the potential side-effects of everolimus and understand that these side-effects are manageable with standard care to optimise patient benefit.

KW - Adverse events

KW - Everolimus

KW - Patient management

KW - Renal cell carcinoma

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=79957566962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957566962&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2011.02.014

DO - 10.1016/j.ejca.2011.02.014

M3 - Article

C2 - 21481584

AN - SCOPUS:79957566962

VL - 47

SP - 1287

EP - 1298

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 9

ER -